Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.

Published byKarin Schumacher Modified over 5 years ago

Similar presentations

Presentation on theme: "Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS."— Presentation transcript:

1 Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS wild-type and (B) RAS wild-type/BRAF wild-type populations. Bev, bevacizumab; EGFRi, epidermal growth factor receptor inhibitor;   P E A K ,  Panitumumab Efficacy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with KRAS WT tumours; PRIME,  Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy; Pmab, panitumumab; VEGFi, vascular endothelial growth factor inhibitor. Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS wild-type and (B) RAS wild-type/BRAF wild-type populations. Bev, bevacizumab; EGFRi, epidermal growth factor receptor inhibitor;   P E A K ,  Panitumumab Efficacy in combination with mFOLFOX6 Against bevacizumab plus mFOLFOX6 in mCRC subjects with KRAS WT tumours; PRIME,  Panitumumab Randomized trial In combination with chemotherapy for Metastatic colorectal cancer to determine Efficacy; Pmab, panitumumab; VEGFi, vascular endothelial growth factor inhibitor. Marc Peeters et al. ESMO Open 2018;3:e000297 Copyright © European Society for Medical Oncology. All rights reserved.

Download ppt "Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS."

Similar presentations

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.

Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer N016966: Efficacy Results  PFS significantly.
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,
Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial)  M. Yoshida, K. Muro, A. Tsuji,
Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.
Early tumor shrinkage (ETS) and depth of response (DpR) to anti-EGFR in (m)CRC helpful surrogates or meaningless endpoints? Marc Peeters MD, PhD Coordinator.

Early tumor shrinkage (ETS) and depth of response (DpR) to anti-EGFR in (m)CRC helpful surrogates or meaningless endpoints? Marc Peeters MD, PhD Coordinator.
(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.

(A) Programmed cell death ligand-1 (PD-L1) expression score was significantly higher in pulmonary adenocarcinomas with grade G2/G3 differentiation as compared.
Axel Grothey Professor of Oncology Mayo Clinic Rochester

Axel Grothey Professor of Oncology Mayo Clinic Rochester
The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.
Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,

Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non- small cell lung cancer  Yoshio Kiyohara, MD, Naoya Yamazaki, MD,
A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,

A proposed treatment model for the decision-making process when choosing between cetuximab continuation vs rechallenge. aTypically patients with left-sided,
Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.

Male patients with non-small cell lung cancer (NSCLC) have a 24% reduction in the risk of disease progression (A). Male patients with non-small cell lung.
Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.
Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.
(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.
A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.

A model for the biological rationale for rechallenge therapy: clonal selection in heterogeneous baseline RAS a wt tumours during anti-EGFR therapy. aAdditional.
Progesterone receptor nuclear morphology patterns in breast cancer.

Progesterone receptor nuclear morphology patterns in breast cancer.
Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.

Invasion front (pushing margin) of the patient's tumour from the primary resection showing a high number of tumour-infiltrating leucocytes, which is characteristic.
Therapeutic validation in orthotopic lung PDX. (A).

Therapeutic validation in orthotopic lung PDX. (A).
Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Similar presentations

Ads by Google